News & Updates
Filter by Specialty:
New algorithm predicts HCC risk in compensated advanced chronic liver disease
A novel algorithm using post-treatment age, albumin, and liver stiffness measurement (LSM), among other parameters, can accurately stratify patients with compensated advanced chronic liver disease (cACLD) according to their de novo hepatocellular carcinoma (HCC) risk, a new study shows.
New algorithm predicts HCC risk in compensated advanced chronic liver disease
19 Dec 2021
Remote management during chemotherapy fails to reduce ED visits, hospitalization
A remote, proactive, and telephone-based management of toxicities in outpatients during adjuvant or neoadjuvant chemotherapy for early-stage breast cancer does not lead to fewer visits to the emergency department (ED) or hospital admissions, a study has shown.
Remote management during chemotherapy fails to reduce ED visits, hospitalization
17 Dec 2021
Adjuvant palbociclib + ET does not improve outcomes vs ET alone in early breast cancer
Adjuvant palbociclib in combination with endocrine therapy (ET) does not improve invasive disease-free survival (iDFS) or secondary endpoints vs ET alone in patients with hormone receptor–positive, HER2-negative early breast cancer, final results of the phase III PALLAS trial have shown.
Adjuvant palbociclib + ET does not improve outcomes vs ET alone in early breast cancer
15 Dec 2021
Cutting first-day dexamethasone dose not recommended for breast cancer patients on anthracycline
In breast cancer patients treated with anthracycline-containing regimens, reducing the first-day dose of dexamethasone does not yield significant gastrointestinal benefit and is not recommended for nausea management, a recent study has found.
